Is There Now An Opportunity In Clarus Corporation (NASDAQ:CLAR)?

By
Simply Wall St
Published
February 18, 2022
NasdaqGS:CLAR
Source: Shutterstock

Clarus Corporation (NASDAQ:CLAR), might not be a large cap stock, but it saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$28.96 and falling to the lows of US$21.12. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Clarus' current trading price of US$21.53 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Clarus’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for Clarus

What's the opportunity in Clarus?

Clarus is currently expensive based on my price multiple model, where I look at the company's price-to-earnings ratio in comparison to the industry average. In this instance, I’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. I find that Clarus’s ratio of 41.66x is above its peer average of 13.45x, which suggests the stock is trading at a higher price compared to the Leisure industry. Furthermore, Clarus’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach levels around its industry peers, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range.

Can we expect growth from Clarus?

earnings-and-revenue-growth
NasdaqGS:CLAR Earnings and Revenue Growth February 18th 2022

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by 50% over the next year, the near-term future seems bright for Clarus. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? CLAR’s optimistic future growth appears to have been factored into the current share price, with shares trading above industry price multiples. At this current price, shareholders may be asking a different question – should I sell? If you believe CLAR should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on CLAR for some time, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the positive outlook is encouraging for CLAR, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

If you'd like to know more about Clarus as a business, it's important to be aware of any risks it's facing. Every company has risks, and we've spotted 5 warning signs for Clarus (of which 1 shouldn't be ignored!) you should know about.

If you are no longer interested in Clarus, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.